Skip to search formSkip to main contentSkip to account menu

suvorexant

Known as: [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone, [(7R)-4-(5-Chlor-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanon, methanone, ((7R)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1H-1,4-diazepin-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)- 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (4)

AzepinesOrexin Receptor AntagonistsSleep Aids, PharmaceuticalTriazoles

Narrower (2)

BelsomraMK 4305
Orexin Receptor Antagonists [MoA]suvorexant 15 MG Oral Tablet [Belsomra]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CNS Drug Development, Lessons Learned, Part 5: How Preclinical and Human Safety Studies Inform the Approval and Subsequent Use of a New Drug—Suvorexant as an Example
This column is the fifth in a series examining the advances being made in central nervous system drug development because of… 
Review
2017
Review
2017
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Geriatric patients often experience insomnia because of physiological and neurological changes that occur during the aging… 
Review
2017
Review
2017
Neurobiological Basis of Hypersomnia.
Review
2016
Review
2016
Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Suvorexant is a hypnotic representing the first-in-class of a new group of agents known as dual orexin receptor antagonists. They… 
2015
2015
Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
2015
2015
Pharmacological Treatment of Insomnia.
Up to 70 million U.S. adults have chronic sleep and wakefulness disorders. Therapies may include prescription medications… 
2014
2014
Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs
Dual Orexin Receptor Antagonists (DORA) bind to both the Orexin 1 and 2 receptors. High resolution crystal structures of the… 
Highly Cited
2012
Highly Cited
2012
Enantioselective synthesis of a dual orexin receptor antagonist.
A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported. Key features of the… 
Review
2012
Review
2012
ACS chemical neuroscience molecule spotlight on Suvorexant.
Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed… 
2012
2012
Update on emerging drugs for insomnia
In recent years, there has been no evidence that the problem of chronic insomnia has faded in the least in US adults; on the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)